Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for treatment-resistant depression
ACTRN12623000667617Phase 2Suspended
- Sponsor
- Swinburne University of Technology
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by Swinburne University of Technology. Primary endpoint: Change in depressive symptoms after two psilocybin-assisted psychotherapy dosing sessions versus placebo-assisted psychotherapy. Started Aug 2023; status: suspended.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12623000667617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000667617.